공지 • Mar 02
Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Mar 29, 2026 Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Mar 29, 2026, at 15:00 Egypt Standard Time. Location: cairo Egypt Board Change • May 14
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공지 • Mar 21
Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Apr 14, 2025 Macro Group Pharmaceuticals (Macro Capital) S.A.E, Annual General Meeting, Apr 14, 2025, at 15:00 Egypt Standard Time. Location: cairo Egypt Reported Earnings • Nov 15
Third quarter 2024 earnings released: EPS: ج.م0.04 (vs ج.م0.12 in 3Q 2023) Third quarter 2024 results: EPS: ج.م0.04 (down from ج.م0.12 in 3Q 2023). Revenue: ج.م164.0m (down 35% from 3Q 2023). Net income: ج.م22.7m (down 67% from 3Q 2023). Profit margin: 14% (down from 27% in 3Q 2023). The decrease in margin was driven by lower revenue. Reported Earnings • Sep 07
Second quarter 2024 earnings released: ج.م0.02 loss per share (vs ج.م0.03 profit in 2Q 2023) Second quarter 2024 results: ج.م0.02 loss per share (down from ج.م0.03 profit in 2Q 2023). Revenue: ج.م95.7m (down 47% from 2Q 2023). Net loss: ج.م10.7m (down 154% from profit in 2Q 2023). Reported Earnings • Apr 20
Full year 2023 earnings released: ج.م0.48 loss per share (vs ج.م0.30 profit in FY 2022) Full year 2023 results: ج.م0.48 loss per share (down from ج.م0.30 profit in FY 2022). Revenue: ج.م526.0m (down 28% from FY 2022). Net loss: ج.م272.7m (down 257% from profit in FY 2022). Valuation Update With 7 Day Price Move • Mar 31
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ج.م2.47, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 24x in the Personal Products industry globally. Total loss to shareholders of 25% over the past year. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ج.م3.57, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 25x in the Personal Products industry globally. Total returns to shareholders of 10% over the past year. Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ج.م3.20, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 27x in the Personal Products industry globally. Total loss to shareholders of 14% over the past year. Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ج.م0.12 (vs ج.م0.10 in 3Q 2022) Third quarter 2023 results: EPS: ج.م0.12 (up from ج.م0.10 in 3Q 2022). Revenue: ج.م252.3m (up 17% from 3Q 2022). Net income: ج.م68.8m (up 18% from 3Q 2022). Profit margin: 27% (in line with 3Q 2022). Upcoming Dividend • Apr 11
Upcoming dividend of ج.م0.11 per share at 2.0% yield Eligible shareholders must have bought the stock before 18 April 2023. Payment date: 31 October 2023. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Higher than average of industry peers (1.7%). Reported Earnings • Mar 07
Full year 2022 earnings released: EPS: ج.م0.30 (vs ج.م0.26 in FY 2021) Full year 2022 results: EPS: ج.م0.30 (up from ج.م0.26 in FY 2021). Revenue: ج.م729.6m (up 23% from FY 2021). Net income: ج.م173.8m (up 18% from FY 2021). Profit margin: 24% (down from 25% in FY 2021). The decrease in margin was driven by higher expenses. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 21
Second quarter 2022 earnings released Second quarter 2022 results: EPS: ج.م0.071. Net income: ج.م40.7m (up ج.م40.7m from 2Q 2021). Over the next year, revenue is forecast to grow 27%, compared to a 9.1% growth forecast for the Personal Products industry in Egypt. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Non Executive Independent Director Sahar El Sallab was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ج.م3.19, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 20x in the Personal Products industry globally. Simply Wall St's valuation model estimates the intrinsic value at ج.م5.21 per share.